Clinical trials: Infliximab
Pediatric Inflammatory Bowel Disease
Durability and Tolerability of Infliximab in Pediatric Inflammatory Bowel Disease Patients: A 10 Year Single Center Experience
There is little data published on the long term durability of infliximab in pediatric patients. In particular a focus on durable remission, frequency of dose/frequency change and switch within class.
- Trial name
- NCT01490528
- Volunteers
- 200 people
- Sponsor
- Cedars-Sinai Medical Center
Crohn Disease
Post-Operative Crohn's Disease Outcome in Children
Objectives: To examine the effect of prophylaxis therapy on clinical and endoscopic disease recurrence in children with Crohn's Disease (CD) following ileo-cecal resection.
- Trial name
- POPCORN (NCT03681652)
- Testing
- Azathioprine, Anti-TNF Drug
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Schneider Children's Medical Center, Israel
Kawasaki Disease, Coronary Aneurysm
Doxycycline Treatment to Prevent Progressive Coronary Artery Dilation in Children With Kawasaki Disease
Kawasaki disease (KD) affects infants and young children causing inflammation of the skin and blood vessels including the coronary arteries of the heart.
- Trial name
- NCT01917721
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Hawaii Pacific Health
Exclusive Enteral Nutrition, Ulcerative Colitis
Combined Application of EEN in the Induction of Remission in PUC
The role of exclusive enteral nutrition (EEN) in the induction of remission in pediatric patients with Crohn's disease had been well documented. But the role of EEN in children with Ulcerative Colitis (UC) was not clear.
- Conditions
- Exclusive Enteral Nutrition, Ulcerative Colitis, Children
- Trial name
- NCT04999241
- Testing
- exclusive enteral nutrition, regular food
- Volunteers
- 40 people
- Sponsor
- Children's Hospital of Fudan University
Inflammatory Bowel Disease, Crohn's Disease
IDeaL Pilot Study - Infliximab Dose to Level: Pilot Study
Crohn's disease (CD) is a lifelong condition of inflammation in the bowel. CD can affect any part of the gastrointestinal tract from mouth to anus.
- Trial name
- IDeaL (NCT02847884)
- Testing
- Infliximab
- Where
- 2 sites in Canada
- Volunteers
- 28 people
- Sponsor
- University of Alberta